![Frontiers | Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes Frontiers | Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes](https://www.frontiersin.org/files/Articles/440649/fendo-10-00080-HTML-r1/image_m/fendo-10-00080-g001.jpg)
Frontiers | Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
![Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications - ScienceDirect Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213177918300416-fx1.jpg)
Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications - ScienceDirect
![Pharmaceuticals | Free Full-Text | Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes Pharmaceuticals | Free Full-Text | Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-14-00586/article_deploy/html/images/pharmaceuticals-14-00586-g001.png?1624331365)
Pharmaceuticals | Free Full-Text | Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
![Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes | Scientific Reports Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-018-33483-y/MediaObjects/41598_2018_33483_Fig1_HTML.png)
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes | Scientific Reports
![Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study - The Lancet Digital Health Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study - The Lancet Digital Health](https://www.thelancet.com/cms/asset/86410633-66f9-484f-820c-0f6c5e3ab6b2/gr1.jpg)
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study - The Lancet Digital Health
![Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials - Chen - 2018 - Diabetes, Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials - Chen - 2018 - Diabetes,](https://dom-pubs.onlinelibrary.wiley.com/cms/asset/1612e8f2-b515-4edc-bc9e-90403794bb63/dom13147-fig-0001-m.jpg)
Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials - Chen - 2018 - Diabetes,
![Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41574-020-0399-8/MediaObjects/41574_2020_399_Fig1_HTML.png)
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology
![Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis - ScienceDirect Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2452302X21001728-fx1.jpg)